[Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009; 361(16): 1570-83.10.1056/NEJMra0901217376041919828534]Search in Google Scholar
[Jin Z, El-Deiry WS. Overview of cell death signalling pathways. Cancer Biol Ther 2005; 4(2): 139-163.10.4161/cbt.4.2.150815725726]Search in Google Scholar
[Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 22(53): 8543-67.10.1038/sj.onc.120710714634618]Search in Google Scholar
[Youle RJ, Strasser A. The BCL-2 family proteins: opposite activities that mediate cell death. Nat. Rev. Mol. Cell Biol 2008; 9(1): 47-59.]Search in Google Scholar
[Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228(4706): 1440-3.10.1126/science.38744303874430]Search in Google Scholar
[Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19(11): 1294-305.10.1101/gad.1304105114255315901672]Search in Google Scholar
[Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, Adams JM, Huang DC. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315(5813): 856-9.10.1126/science.113328917289999]Search in Google Scholar
[Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh J, Cheng E. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006; 8(12): 1348-58.10.1038/ncb149917115033]Search in Google Scholar
[Sax JK, El Deiry WS. p53 downstream targets and chemosensitivity. Cell Death Differ 2003; 10(4): 413-17.10.1038/sj.cdd.440122712719718]Search in Google Scholar
[Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001; 20(2): 240-51.10.1038/sj.onc.120406711313951]Search in Google Scholar
[Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303(60): 1010-4.10.1126/science.109273414963330]Search in Google Scholar
[Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. 2009; 9(7): 501-7.10.1038/nrc2663]Search in Google Scholar
[Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets. 2009; 9(3): 307-19.10.2174/156800909788166547]Search in Google Scholar
[Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000; 60(21): 6101-10.]Search in Google Scholar
[Hockenbery DM. Targeting mitochondria for cancer therapy. Environ Mol Mutagen. 2010; 51(5): 476-89.10.1002/em.20552]Search in Google Scholar
[Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med. 1987; 317(19): 1185-1189.10.1056/NEJM198711053171904]Search in Google Scholar
[Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986; 47(1): 19-28.10.1016/0092-8674(86)90362-4]Search in Google Scholar
[Bertheas MF, Bachy M, Magaud JP, Rimokh R, Vasselon C, Berger F, Oriol PC, Jaubert J, Reynaud J, Brizard CP, et al. t(2;18) and t(18;22) variant chromosomal translocations in B cell malignancies. Leuk Lymphoma. 1992; 8(3): 197-200.10.3109/104281992090549051490147]Search in Google Scholar
[Adachi M, Tefferi A, Greipp PR, Kipps TJ, Tsujimoto Y. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med 1990; 171(2): 559-64.10.1084/jem.171.2.55921877272106002]Search in Google Scholar
[Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993; 82(6): 1820-1828.10.1182/blood.V82.6.1820.1820]Search in Google Scholar
[Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood. 1997; 90(3): 1168-1174.10.1182/blood.V90.3.1168]Search in Google Scholar
[Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006; 43(1): 1-67.10.1080/1040836050029562616531274]Search in Google Scholar
[Tothova E, Fricova M, Stecova N, Kafkova A, Elbertova A. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma 2002; 49(3): 141-44.]Search in Google Scholar
[Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nuñez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavourable histology and N-myc amplification. Am J Pathol 1993; 143(6): 1543-50.]Search in Google Scholar
[Jiang SX, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995; 177(2): 135-8.10.1002/path.1711770206]Search in Google Scholar
[Molica S, Mannella A, Dattilo A, Levato D, Iuliano F, Peta A, Consarino C, Magro S. Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis. Haematologica 1996; 81(4): 302-9.]Search in Google Scholar
[Klobusická M, Kusenda J, Babusíkova O. Expression of p53 and bcl-2 proteins in acute leukemias: an immunocytochemical study. Neoplasma 2001; 48(6): 489-95.]Search in Google Scholar
[Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994; 424(1): 47-51.10.1007/BF00197392]Search in Google Scholar
[Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148(5): 1567-76.]Search in Google Scholar
[Singhal S, Amin KM, Kruklitis R, Marshall MB, Kucharczuk JC, DeLong P, Litzky LA, Kaiser LR, Albelda SM. Differentially expressed apoptotic genes in early stage lung adenocarcinoma predicted by expression profiling. Cancer Biol Ther 2003; 2(5): 566-71.10.4161/cbt.2.5.514]Search in Google Scholar
[Watanabe J, Kushihata F, Honda K, Mominoki K, Matsuda S, Kobayashi N. BclxL overexpression in human hepatocellular carcinoma. Int J Oncol 2002; 21(3): 515-9.]Search in Google Scholar
[Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J, Reed JC. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 1997; 150(3): 805-14.]Search in Google Scholar
[Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 1996; 56(10): 2422-7.]Search in Google Scholar
[Račay P, Hatok J, Hudeček J, Chudej J, Jurečeková J, Dobrota D. Transcription of genes of p53-dependent apoptosis in acute leukaemia. Int J Mol Med 2008; 22(6): 833-9.]Search in Google Scholar
[Gobé G, Rubin M, Williams G, Sawczuk I, Buttyan R. Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Invest 2002; 20(3): 324-32.10.1081/CNV-120001177]Search in Google Scholar
[Cho-Vega JH, Rassidakis GZ, Admirand JH, Oyarzo M, Ramalingam P, Paraguya A, McDonnell TJ, Amin HM, Medeiros LJ. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol 2004; 35(9): 1095-100.10.1016/j.humpath.2004.04.018]Search in Google Scholar
[Rassidakis GZ, Lai R, McDonnell TJ, Cabanillas F, Sarris AH, Medeiros LJ. Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. Am J Pathol 2002; 160(6): 2309-10.10.1016/S0002-9440(10)61178-9]Search in Google Scholar
[Wuillème-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M, Bataille R. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19(7): 1248-52.10.1038/sj.leu.240378415902294]Search in Google Scholar
[Wong RP, Khosravi S, Martinka M, Li G. Myeloid leukemia-1 expression in benign and malignant melanocytic lesions. Oncol Rep 2008; 19(4): 933-7.10.3892/or.19.4.933]Search in Google Scholar
[Lee HW, Lee SS, Lee SJ, Um HD. Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res 2003; 63(5): 1093-100.]Search in Google Scholar
[Wilson JW, Nostro MC, Balzi M, Faraoni P, Cianchi F, Becciolini A, Potten CS. Bcl-w expression in colorectal adenocarcinoma. Br J Cancer 2000; 82(1): 178-85.10.1054/bjoc.1999.0897236318510638987]Search in Google Scholar
[MacCarthy-Morrogh L, Wood L, Brimmell M, Johnson PW, Packham G. Identification of a novel human BCLX promoter and exon. Oncogene 2000; 19(48): 5534-8.10.1038/sj.onc.120394911114731]Search in Google Scholar
[Yamaguchi H, Inokuchi K and Dan K: The study for loss of bcl-xs expression as a prognostic factor in acute myeloid leukemia. Leuk Res 2002; 26(12): 1119-23.10.1016/S0145-2126(02)00061-9]Search in Google Scholar
[Soussi T. p53 alterations in human cancers: more questions than answers. Oncogene 2007; 26(15): 2145-56.10.1038/sj.onc.1210280]Search in Google Scholar
[Inoue K, Kohno T, Takakura S, Hayashi Y, Mizoguchi H, Yokota J. Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines. Leuk Res 2000; 24(3): 255-62.10.1016/S0145-2126(99)00182-4]Search in Google Scholar
[Marone M, Ferrandina G, Macchia G, Mozzetti S, de Pasqua A, Benedetti-Panici P, Mancuso S, Scambia G. Bcl-2, Bax, Bcl-x(L) and Bcl-x(S) expression in neoplastic and normal endometrium. Oncology 2000; 58(2): 161-8.10.1159/00001209410705244]Search in Google Scholar
[Gil J, Yamamoto H, Zapata JM, Reed JC, Perucho M. Impairment of the proapoptotic activity of Bax by missense mutations found in gastrointestinal cancers. Cancer Res 1999; 59(9): 2034-7.]Search in Google Scholar
[Rampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J. C., Perucho, M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275(5302): 967-9.10.1126/science.275.5302.9679020077]Search in Google Scholar
[Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, Reed JC. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996; 149(5): 1449-57.]Search in Google Scholar
[Kondo S, Shinomura Y, Miyazaki Y, Kiyohara T, Tsutsui S, Kitamura S, Nagasawa Y, Nakahara M, Kanayama S, Matsuzawa Y. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res 2000; 60(16): 4328-30.]Search in Google Scholar
[Wani KM, Huilgol NG, Hongyo T, Shah K, Chatterjee N, Nair CK, Nomura T. Genetic alterations in the coding region of the bak gene in uterine cervical carcinoma. Br J Cancer 2003; 88(10): 1584-6.10.1038/sj.bjc.6600944237711112771926]Search in Google Scholar
[Kang MH, Reynolds P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15(4): 1126-32.10.1158/1078-0432.CCR-08-0144318226819228717]Search in Google Scholar
[Choi YH. Apoptosis of U937 human leukemic cells by sodium butyrate is associated with inhibition of telomerase activity. Int J Oncol 2006; 29(5): 1207-13.10.3892/ijo.29.5.1207]Search in Google Scholar
[Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010; 28(10): 1069-78.10.1038/nbt.1678302297220944599]Search in Google Scholar
[Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007; 110(5): 943-54.10.1002/cncr.2289117647267]Search in Google Scholar
[Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: Facilitating apoptosis in cancer treatment. Antisense Nucleic Acid Drug Dev 2002; 12(3): 193-213.10.1089/10872900276022079812162702]Search in Google Scholar
[O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic chronic lymphocytic leukemia. Blood 2009; 113(2): 299-305.10.1182/blood-2008-02-137943496837218931344]Search in Google Scholar
[Di Cresce C, Koropatnick J. Antisense treatment in human prostate cancer and melanoma. Curr Cancer Drug Targets. 2010; 10(6): 555-65.10.2174/15680091079185945220482488]Search in Google Scholar
[Dalafave DS, Prisco G Inhibition of antiapoptotic BCL-XL, BCL-2 and MCL-1 proteins by small molecule mimetics. Cancer Inform. 2010; 9: 169-77.10.4137/CIN.S5065293582020838611]Search in Google Scholar
[Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer J, Kunzer AR, Letai A, Li Ch, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435(7042): 677-81.10.1038/nature0357915902208]Search in Google Scholar
[Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P, Dyer MJS, Cohen GM A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 2008; 15(5), 820-30.10.1038/cdd.2008.2518309326]Search in Google Scholar
[Tse Ch, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson F, Marsh K C, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68(9): 3421-8.10.1158/0008-5472.CAN-07-583618451170]Search in Google Scholar
[Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29(7): 909-16.10.1200/JCO.2010.31.6208466828221282543]Search in Google Scholar
[Kögel D, Fulda S, Mittelbronn M. Therapeutic exploitation of apoptosis and autophagy for glioblastoma. Anticancer Agents Med Chem 2010; 10(6): 438-49.10.2174/187152061100906043820879985]Search in Google Scholar
[Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Bélec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, Shore GC. Small molecule obatoclax (GX 15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104(49), 19512-7.10.1073/pnas.0709443104214832018040043]Search in Google Scholar
[Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C., Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G. A phase I study of the pan Bcl-2 family inhibitor obatoclax mesylate in patients with advances hematologic malignancies. Clin Cancer Res 2008; 14(24), 8295-301.10.1158/1078-0432.CCR-08-099919088047]Search in Google Scholar
[Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL, Berger MS, Viallet J, Marshall JL. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 2010; 16(15): 4038-45.10.1158/1078-0432.CCR-10-0822370324520538761]Search in Google Scholar
[Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008; 68(9): 3413-20.10.1158/0008-5472.CAN-07-1919409612718451169]Search in Google Scholar
[Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol. 2010; 66(6): 1079-85.10.1007/s00280-010-1265-5294562520165849]Search in Google Scholar
[Oliver CL, Bauer JA, Wolker KG, Ubell ML, Narayan A. In vitro effect of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 2004; 10(22): 7757-63.10.1158/1078-0432.CCR-04-055115570010]Search in Google Scholar
[Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15(9): 3172-6.10.1158/1078-0432.CCR-08-2985292191519366825]Search in Google Scholar
[Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 2010; 5(10): 1637-43.10.1097/JTO.0b013e3181e8f4dc20808253]Search in Google Scholar